Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases

Lung Cancer

Volumn 87, Issue 1, 2015, Pages 77-79

  Rusch, Andreas ^a   Ziltener, Gabriela ^a   Nackaerts, Kristiaan ^b   Weder, Walter ^a   Stahel, Rolf A ^a,c   Felley Bosco, Emanuela ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

Author keywords

BAP1; BAP1 cancer syndrome; Germline mutation; Germline mutation screening; Mesothelioma; Tumor predisposition syndrome

Indexed keywords

DNA; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; ARTICLE; BRCA 1 ASSOCIATED PROTEIN 1 GENE; CARCINOGENESIS; CONTROLLED STUDY; ELECTROPHORESIS; EXON; FEMALE; GENE SEQUENCE; GENETIC SCREENING; GERMLINE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PLEURA MESOTHELIOMA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; WILD TYPE; AGED; CANCER STAGING; CLINICAL TRIAL; DNA SEQUENCE; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; MULTICENTER STUDY; PLEURAL NEOPLASMS; TUMOR SUPPRESSOR GENE;

AGED; EXONS; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84922222148     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.10.017     Document Type: Article

References (23)

1. Bertino P., Carbone M., Pass H. Chemotherapy of malignant pleural mesothelioma. Expert Opin Pharmacother 2009, 10:99-107.
2. Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011, 43:668-672.
3. Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A., et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998, 16:1097-1112.
4. Ventii K.H., Devi N.S., Friedrich K.L., Chernova T.A., Tighiouart M., Van Meir E.G., et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008, 68:6953-6962.
5. Mallery D.L., Vandenberg C.J., Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J 2002, 21:6755-6762.
6. Kittler R., Pelletier L., Heninger A.K., Slabicki M., Theis M., Miroslaw L., et al. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol 2007, 9:1401-1412.
7. Yu H., Mashtalir N., Daou S., Hammond-Martel I., Ross J., Sui G., et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 2010, 30:5071-5085.
8. Machida Y.J., Machida Y., Vashisht A.A., Wohlschlegel J.A., Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009, 284:34179-34188.
9. Murali R., Wiesner T., Scolyer R.A. Tumours associated with BAP1 mutations. Pathology 2013, 45:116-126.
10. Carbone M., Yang H., Pass H.I., Krausz T., Testa J.R., Gaudino G. BAP1 and cancer. Nat Rev Cancer 2013, 13:153-159.
11. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823.
12. Harbour J.W., Onken M.D., Roberson E.D., Duan S., Cao L., Worley L.A., et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
13. Yoshikawa Y., Sato A., Tsujimura T., Emi M., Morinaga T., Fukuoka K., et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012, 103:868-874.
14. Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011, 43:1022-1025.
15. Carbone M., Ferris L.K., Baumann F., Napolitano A., Lum C.A., Flores E.G., et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012, 10:179.
16. Wiesner T., Obenauf A.C., Murali R., Fried I., Griewank K.G., Ulz P., et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011, 43:1018-1021.
17. Abdel-Rahman M.H., Pilarski R., Cebulla C.M., Massengill J.B., Christopher B.N., Boru G., et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011, 48:856-859.
18. Popova T., Hebert L., Jacquemin V., Gad S., Caux-Moncoutier V., Dubois-d'Enghien C., et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013, 92:974-980.
19. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996, 14:1-12.
20. Firmann M., Mayor V., Vidal P.M., Bochud M., Pecoud A., Hayoz D., et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 2008, 8:6.
21. Aoude L.G., Vajdic C.M., Kricker A., Armstrong B., Hayward N.K. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res 2013, 26:278-279.
22. Njauw C.N., Kim I., Piris A., Gabree M., Taylor M., Lane A.M., et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS ONE 2012, 7:e35295.
23. Sauna Z.E., Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 2011, 12:683-691.